On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
MondayMay 03, 2021 1:10 pm

NetworkNewsBreaks – Tesla Inc. (NASDAQ: TSLA) Featured in Analysis Report

Tesla (NASDAQ: TSLA), an American electric vehicle (“EV”) and clean energy company, was featured in a recent analysis report that discussed its clear dominance and distinction from the rest of the pack. The report, written by LikeFolio Founder Andy Swan, reads, “Tesla has already released 21Q1 delivery stats. The company delivered 184,800 cars (+110% YoY, +2% QoQ, and last quarter was a record-setter). It's important to note that these deliveries tilt toward the cheaper Model 3 and Y. LikeFolio data confirms consumer demand for Tesla vehicles is booming -- and our data is typically very leading. Purchase intent mentions increased…

Continue Reading

MondayMay 03, 2021 12:12 pm

NetworkNewsBreaks – Pinterest Inc. (NYSE: PINS) Featured in Analysis Report

Pinterest (NYSE: PINS), the operator of a popular social networking site for sharing photos, ideas, recipes, and more, was featured in a recent analysis report that discussed its impressive performance. The report, written by LikeFolio Founder Andy Swan, reads, “Last quarter, PINS reported 459 million monthly active users, +37% YoY. LikeFolio's mention metric is a good post to gauge Pinterest usage...and in the last quarter, we recorded significant YoY growth: +68%. This is impressive, considering the chart captures English-speaking mentions. We know the international segment is Pinterest's major growth machine, now comprising ~79% of total users.” About Pinterest Inc. Pinterest…

Continue Reading

MondayMay 03, 2021 11:44 am

NetworkNewsBreaks – Apple Inc. (NASDAQ: AAPL) Featured in Analysis Report

Apple (NASDAQ: AAPL), an American multinational technology company, was featured in a recent analysis report that discussed its performance following a pandemic-induced surge. The report, written by LikeFolio Founder Andy Swan, reads, “In 21Q2, Apple demand growth slowed: +6% YoY. In the prior quarter, demand increased +17% YoY. Seasonally speaking, this is not a big quarter for AAPL (Q4 and Q1 encompass keynote drops and holiday season). Work-from-home trends boosted iPads and Macs last year, but normalization is occurring and evident in a product breakdown: comparative weakness across the board on a YoY basis. Apple Happiness is stable (64% positive),…

Continue Reading

FridayApr 30, 2021 11:20 am

NetworkNewsBreaks – Nkarta, Inc. (NASDAQ: NKTX) Featured in Mizuho Securities Research Report

Nkarta, Inc. (NASDAQ: NKTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, Nkarta press released IND clearance for its off-the-shelf CD19 CAR-NK product candidate NKX019 in relapsed/refractory B-cell malignancies. The company expects to dose the first patient in 2H21 (in line with previous language). All good here, continuing with the mantra that is a co-lead program at Nkarta along w/ NKX101.” To request access to the full report, visit http://nnw.fm/SaZ9d About Nkarta, Inc. Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (“NK”) cell…

Continue Reading

WednesdayApr 28, 2021 10:16 am

NetworkNewsBreaks – Axsome Therapeutics, Inc. (NASDAQ: AXSM) Featured in Mizuho Securities Research Report

Axsome Therapeutics (NASDAQ: AXSM) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “AXS-05 Accepted and Granted Priority Review for Major Depressive Disorder: Axsome announced today that the FDA has accepted the company's New Drug Application (‘NDA’) for AXS-05 for the major depressive disorder (‘MDD’) indication. Importantly, the FDA has also granted the application Priority Review status, which shortens the review time from ten months to six months and sets up a Prescription Drug User Fee Act (‘PDUFA’) target action date of August 22, 2021. The news is in-line with our expectations,…

Continue Reading

FridayApr 23, 2021 3:06 pm

NetworkNewsBreaks – Coherus BioSciences, Inc. (NASDAQ: CHRS) Featured in Mizuho Securities Research Report

Coherus BioSciences (NASDAQ: CHRS) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, Coherus announced that toripalimab (tori) in combination with chemo significantly prolonged PFS and OS in patients with advanced esophageal squamous cell carcinoma (‘ESCC’), compared w/ chemo alone. Despite the press release not containing numbers, we had a look at the benchmark data for anti-PD1s in combo w/ chemo being studied in this indication, as well as its potential market size, to start to do work around it. Overall, an incremental win for Coherus as the Junshi thesis…

Continue Reading

ThursdayApr 22, 2021 2:12 pm

NetworkNewsBreaks – Biogen Inc. (NASDAQ: BIIB) Featured in Mizuho Securities Research Report

Biogen (NASDAQ: BIIB) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Housekeeping: (1) Revenues came in line, but would have slightly missed if you back out the $40MM benefit of inventory in Spinraza ROW, and (2) there was a slight bump to EPS guidance for the year on reduced R&D. Note, Rituxan and Tecfidera erosion is occurring faster than expected. . . . Aducanumab: Language largely unchanged -- still in the guide. The slides discuss 600 clinical sites in the US that will be able to treat "shortly after potential approval".…

Continue Reading

ThursdayApr 15, 2021 11:16 am

NetworkNewsBreaks – BridgeBio Pharma, Inc. (NASDAQ: BBIO) Featured in Mizuho Securities Research Report

BridgeBio Pharma, Inc. (NASDAQ: BBIO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning BridgeBio announced seven collaborations with US and Canadian academic and research institutions to take its total up to 20. It caught my eye. . . . It's especially timely, as one of things that is currently bubbling up in my conversations with folks is this topic of portfolio-based biotechs. We're seeing more of this now more than ever. Obviously, there is BridgeBio. Centessa launched a month ago with a $250MM Series A. Marc Appel's Orange Grove…

Continue Reading

ThursdayApr 15, 2021 11:15 am

NetworkNewsBreaks – Cytokinetics, Inc. (NASDAQ: CYTK) Featured in Mizuho Securities Research Report

Cytokinetics, Inc. (NASDAQ: CYTK) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Well, we are now well into April (yay for spring!), and if you're not aware, April 2021 is the designated month listed in the primary completion field on clinicaltrials.gov for CYTK's CK-274 Ph2 REDWOOD-HCM trial. This is going to be an important readout for CYTK and data is expected "mid-2021," per CYTK (note: we think May, unless CYTK clarifies with more granularity). Recall, the elevator pitch for CYTK is MYOK's mavacamten was sold to BMY for ~$13Bn. CYTK's CK-274…

Continue Reading

FridayApr 09, 2021 10:47 am

NetworkNewsBreaks – Roblox Corporation (NYSE: RBLX) Featured in Analysis Report

Roblox (NYSE: RBLX), focused on bringing the world together through play, was featured in a recent LikeFolio analysis report that discussed its performance since its debut into public trading. The report, written by LikeFolio Founder Andy Swan, reads, “On Monday, several investment banks initiated buy ratings for the video game company Roblox (NYSE: RBLX). Although the stock has been trading publicly for less than a month, LikeFolio has maintained a bullish outlook from the onset of coverage. Purchase intent mentions for the gaming platform rose to a new ATH in 21Q1 (ended 3/31), up +79% from the prior year. Shares…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217